Skip to content

Cerebrovascular EveNts in Patients Undergoing TranscathetER Aortic Valve Implantation With Balloon-expandable Valves Versus Self-expandable Valves.

Cerebrovascular EveNts in Patients Undergoing TranscathetER Aortic Valve Implantation With Balloon-expandable Valves Versus Self-expandable Valves.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03588247
Acronym
CENTER
Enrollment
12000
Registered
2018-07-17
Start date
2017-08-01
Completion date
2023-01-01
Last updated
2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis

Brief summary

The aim of this collaborative analysis is to evaluate stroke rates and mortality in patients undergoing TAVI with the self-expandable MCV prosthesis compared to the balloon-expandable ES valve. In the absence of large randomized controlled trials, we will conduct a large collaborative patient-pooled meta-analysis on 30-day stroke and mortality in patients undergoing primary transfemoral TAVI with either MCV or ES valve.

Detailed description

The main aim of this patient-pooled analyses is to compare stroke rates and mortality in patients undergoing TAVI with the self-expandable MCV prosthesis compared to the balloon-expandable ES valve. However, this collaboration may also be used to compare various outcomes. Studies were included if they complied with the following requirements: original prospective studies, including patients with aortic valve stenosis treated with transfemoral TAVI of native valves and reporting of 30 day stroke outcomes according to VARC criteria or other specified corresponding criteria . Moreover, to be included studies had to report both the use of self-expandable MCV prosthesis and the balloon-expandable ES valve in more than 50 patients in each arm to ensure experience in use of the valves. Studies were excluded if they only addressed patients undergoing valve-in-valve and re-do procedures or bicuspid valves or included the same study population. Principal Investigators of these studies were approached for collaboration.

Interventions

PROCEDUREtranscatheter aortic valve implantation

Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* patients undergoing transfemoral transcatheter aortic valve procedures

Exclusion criteria

* valve-in-valve procedures, other acces routes than transfemoral

Design outcomes

Primary

MeasureTime frameDescription
Mortality30 daysDeath during the first month after TAVI
Stroke30 daysStroke during the first month after TAVI

Secondary

MeasureTime frameDescription
Pacemaker implantation30 daysPacemaker during the first month after TAVI
Bleeding30 daysMajor or life-threatening bleeding during the first month after TAVI
New onset atrial fibrillation30 daysNew onset atrial fibrillation during the first month after TAVI
Myocardial infarction30 daysMyocardial infarction during the first month after TAVI

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026